Out-licensing: Oncology/Tumor (other)

Up-to-date access to technology licensing opportunities worldwide.

Out-licensing
Browse

Licensing opportunities

Displaying 11..20 of 36 - per page Previous page Next page
Order by

Ultrasonic Waves with Nanovessels or Tethered Nanotube/Monoclonal Antibody Composites for Cancer Therapy

Compositions and methods of use for delivering therapeutic agents transported on or inside nanostructures to target sites for cancer therapy More

Methods of Treating Cancer Using Pyridine Carboxaldehyde Pyridine Thiosemicarbazone Radiosensitizing Agents

Methods of treating cancer and other tumors by coadministration of a radiosensitizing amount of Triapine and ionizing radiation More

1,2-Dihydroellipticines with Activity Against CNS-Specific Cancer Cell Lines

Compounds which cross the blood brain barrier and retain activity against CNS specific cancer cell lines More

Use of Inhibitors of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase as a Modality in Cancer Therapy

Lovastatin and simvastatin and their analogs for cancer treatment More

Deoxyhypusine Hydroxylase

Inventors at the National Institutes of Health have recently characterized and cloned both the yeast and human recombinant versions of the enzyme deoxyhypusine hydroxylase (DOHH) that catalyzes the final step in the modification of eIF5A. More

BIO-004 - CANCER - Novel siRNA-Based Strategy for Treatment of Cancer Through Silencing of Genes Involved in Tumor Protection

Our invention relates to a novel anti-cancer therapy involving the silencing of tumour-derived immunosuppressive genes using siRNA. More

Fluorescent Imaging and Photodynamic Treatment of Tumors

Allows tumors to be visualized in situ, with high sensitivity and without hazardous radioactive probes More

Protein-tyrosine Phosphotase Inhibitors as Inhibitors of Human Tyrosyl-DNA Phosphodiesterase (Tdp1) and Methods of Treating Disorders

Me-3,4 dephostatin, a Tdp1 inhibitor. More

Synthetic Analogs of Juxtamembrane Domain of IGF-1 Receptor as Anti-Cancer Agents

These analogs were found to be potent inhibitors of IGF-1-mediated cell signaling and cancer cell growth, providing more binding specificity with less likelihood of significant toxic effects. More

Prolactin Receptor Antibodies as a Diagnostic Marker and Therapeutic Agent for Cancer

This technology describes several antibodies, both polyclonal and monoclonal, to the prolactin receptor. More

Displaying 11..20 of 36 - per page Previous page Next page
Order by

Your selection

Therapeutic target: Oncology del; Tumor (other) del

Browse By

Industry sector: Animal health; Biotechnology; Diagnostic; Drug delivery; Drug discovery; Medical device; Pharmaceutical; Research tools
Development phase: Early Stage; Preclinical; Phase I; Phase I/II; Phase II; Phase III; Phase III/IV; Preregistration; Registered

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us